Rare Diseases

 

Apremilast Reduces Oral Ulcers in Behçet’s Syndrome

January 28, 2020

Apremilast (Otezla, Celgene) resulted in a greater reduction in the number of oral ulcers associated with Behçet’s syndrome than placebo, say researchers recently writing in the New England Journal of Medicine.

New Treatment Option for Behçet’s Disease

July 22, 2019

On Friday, the U.S. Food and Drug  Administration approved apremilast (Otezla, Celgene) for the treatment of oral ulcers associated with Behçet’s disease, a rare, chronic, multisystem inflammatory condition that affects approximately five in 100,000 people in the U.S.